Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.69 |
| ▸ | MMP2 | P08253 | 3/20 | 0.60 |
| ▸ | MMP9 | P14780 | 3/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 3/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP3 | P08254 | 1/20 | 0.55 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12247713 | 0.91 | FOLH1 (0.63) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL12636074 | 0.88 | MAPT (0.61) | FOLH1 | |
| SCHEMBL806151 | 0.88 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL4561005 | 0.88 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL464715 | 0.88 | FOLH1 (0.78) | FOLH1MMP2MMP9CPB1CPB2 | |
| Trifluoroacetic Acid SCHEMBL8892389 | 0.86 | FOLH1 (0.63) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL18659633 | 0.85 | CTSL (0.62) | FOLH1CPB1CPB2SIRT2 | |
| SCHEMBL20677210 | 0.85 | FOLH1 (0.73) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL7296591 | 0.85 | FOLH1 (0.73) | FOLH1MMP2MMP9CPB1CPB2 | |
| SCHEMBL4173691 | 0.84 | FOLH1 (0.72) | FOLH1MMP2MMP9CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263040-B2 | contrast agents for necrosis imaging, diagnosis of changes in the lymphatic system, inflammatory diseases, cardiovascular diseases, tumour imaging; radioactive materials use in radiotherapy | BAYER SCHERING PHARMA AG (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2089362-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG GROUP, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080159954-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008046463-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG GROUP, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1904462-A2 | COMPLEXES CONTAINING PERFLUOROALKYL, METHOD FOR THE PRODUCTION AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1307237-B9 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1307237-B1 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007009637-A2 | COMPLEXES CONTAINING PERFLUOROALKYL, THEIR USE AS CONTRAST MEDIA FOR NMR, X-RAY AND RADIO DIAGNOSIS AND RADIOTHERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070020183-A1 | Perfluoroalkyl-containing complexes, process for their production as well as their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1307446-B1 | PERFLUOROALKYL-CONTAINING COMPLEXES COMPRISING SUGAR RESIDUES, METHOD FOR PRODUCING THE SAME AND USE THEREOF | SCHERING AG (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6641797-B2 | As contrast media for the visualization of malignant tumors, lymph nodes and necrotic tissue | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| EP-1307236-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| EP-1307237-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| EP-1307446-A1 | PERFLUOROALKYL-CONTAINING COMPLEXES COMPRISING SUGAR RESIDUES, METHOD FOR PRODUCING THE SAME AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002013874-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013875-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002014309-A1 | PERFLUOROALKYL-CONTAINING COMPLEXES COMPRISING SUGAR RESIDUES, METHOD FOR PRODUCING THE SAME AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159954-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | TFRC, FCGRT, SLC39A14 | FOLH1 1367/4885MMP2 2451/4885MMP9 1339/4885 |
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | FGB, MSR1, FFAR1 | FOLH1 1983/4885MMP2 1810/4885MMP9 1502/4885 |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | FOLH1 2668/4885MMP2 2091/4885MMP9 949/4885 |
| US-20070020183-A1 | Perfluoroalkyl-containing complexes, process for their production as well as their use | AFF1, FRG1, AFF2 | FOLH1 2572/4885MMP2 4422/4885MMP9 2982/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | FOLH1 2292/4885MMP2 2621/4885MMP9 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.